LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT

BACKGROUND: MAPK pathway is the hallmark of pediatric low grade gliomas (pLGGs); hyperactivation of mTOR (mammalian target of rapamycin) might be a suitable biomarker for therapeutic response. We investigated the feasibility of Everolimus, mTOR inhibitor, in patients affected by pLGGs. METHODS: Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Cacchione, Antonella, Miele, Evelina, Lodi, Maria Chiara, Carai, Andrea, Colafati, Giovanna Stefania, Camassei, Francesca Diomedi, Locatelli, Franco, Mastronuzzi, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715476/
http://dx.doi.org/10.1093/neuonc/noaa222.400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715476/
http://dx.doi.org/10.1093/neuonc/noaa222.400

Ejemplares similares